Attention IASLC Voting Members!!

Check your email for "Your Vote Matters: Cast Your Ballot on IASLC Bylaws Today" to cast your ballot, or contact membership@iaslc.org

Journals

Explore novel research, stay current on clinical trials, and find answers to your clinical care questions in case reports.
Covers of JTO CRR and JPO

Complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.

JTO CRR in PubMed Central and Web of Science!

JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 21.0, JTO is among the top 4% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews, and opinion pieces. JTO CRR, IASLC’s open-access companion title, publishes a range of manuscripts, from subset analyses of published trials to high-quality case reports. JTO CRR has an Impact Factor of 3.0 and is indexed in PubMed and Web of Science. 

JTO 2023 Impact Factor
JTO CRR 2023 Impact Factor

JTO by the Numbers

13
out of 322 in Oncology Journals
2
out of 100 in Respiratory Journals
21.0
Impact Factor (up from 20.4 in 2022)
1,704%
increase in 6 years full-text article downloads
Alex Adjei

EDITOR-IN-CHIEF, JTO ON 2023 IMPACT FACTOR

Alex A. Adjei, MD, PhD, FACP

"JTO's impact factor for 2023 has risen to 21, making it only the second respiratory journal (after Lancet Respiratory Medicine) with an impact factor above 20. More importantly, it is the only thoracic oncology journal with an impact factor greater than 10. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals, and we now rank 13th  out of 322 oncology journals.  This achievement is a testament to the exemplary work of our editorial board and our editorial office, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology."

JTO CRR By the Numbers

142
out of 322 Oncology Journals
37
out of 100 Respiratory Journals
3.0
2023 Impact Factor
Dr. Emily Stone

EDITOR-IN-CHIEF, JTO CRR ON 2023 IMPACT FACTOR

Emily Stone, MBBS, PhD, FRACP

“The JTO CRR team is celebrating our first impact factor at 3.0, and we wish to thank everyone who made it possible – the authors, reviewers, editors, and the IASLC. We are thrilled to make such a terrific start, which truly reflects our commitment to excellence in science.”

Most-Cited Journal of Thoracic Oncology Articles in 2023

Recent journal articles

Discover the JTO

JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:

JTO RSS Feed

JTO articles

Subscribe to receive alerts about new content from JTO 

Searches, Citations, or Collection

Searches, Citations or Collection

Subscribe to receive alerts about saved searches, citations, or collections

Monthly Quick Poll

Journals stock poll

Participate in the monthly Quick Poll

Journal of Thoracic Oncology Impact Factor Continues to Increase

JTO cover 1

The JTO, the official journal of the IASLC, now ranks 13th out of all 322 oncology journals and 2nd out of all 100 respiratory system journals.

More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 1 week to initial decision, and an average of 1.6 weeks for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.

JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.

JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to JTO@iaslc.org

New JTO Collections

JTO

Statistics in Oncology Series

This collection of articles covers fundamental statistical principles and recommendations for best practice.

JTO

Lung Cancer Worldwide Editorials

These articles offer a synopsis of lung cancer epidemiology, screening, prevention, diagnosis and therapy in different countries all over the world.

Discover the JTO CRR

Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.

JTO CRR RSS Feed